finance.yahoo.com Analyst action
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), one of the world's largest pharmaceutical companies with a major focus on oncology, ended its Phase III eVOLVE-Lung02 trial after an independent committee concluded that volrustomig combined with chemotherapy was unlikely to outperform existing treatment options in improving progression-free or overall survival. The study covered 895 patients with metastatic non-small-cell …